BGT 226

Drug Profile

BGT 226

Alternative Names: BGT226; NVP-BGT226

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator Novartis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 13 Oct 2010 Novartis completes a phase I/II trial in Solid tumours in USA, Canada and Spain (NCT00600275)
  • 21 Jul 2010 Phase I/II development is ongoing USA, Canada and Spain
  • 02 Mar 2010 A phase I/II trial in solid tumours is ongoing in USA, Canada and Spain (NCT00600275)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top